Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD14 Purified Low Endotoxin

Anti-Hu CD14 Purified Low Endotoxin

Regulatory status

RUO

Antigen

CD14

Clone

MEM-18

Format

Purified Low Endotoxin

Reactivity

Human, Non-human primates

Application

ELISA, IP, WB, FC (QC tested), FUNC

Variant

0.1 mg

12-212-C100

In stock

130.00 USD

Variant

0.1 mg

12-212-C100

In stock

130.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The antibody MEM-18 reacts with CD14, a 53-55 kDa GPI (glycosylphosphatidylinositol)-linked extracellular membrane glycoprotein expressed on monocytes, macrophages and weakly on granulocytes; also expressed by most tissue macrophages. In human, the epitope recognized by MEM-18 is located between amino acids 57-64.

Workshop

HLDA III: WS Code M 253; HLDA IV: WS Code M 314; HLDA V: WS Code M MA087; HLDA VI: WS Code M MA95

Application

ELISA, IP, WB, FC (QC tested), FUNC

Application details

ELISA: The antibody MEM-18 has been tested as the detection antibody in a sandwich ELISA for analysis of human CD14 in combination with antibody B-A8 (cat. no. 11-304-C100).
Functional application: The antibody MEM-18 completely blocks binding of fluorescein (FITC) labeled bacterial LPS to the monocyte surface and it also blocks the binding of CD14 to the extracellular TLR2 domain.
Flow cytometry: recommended dilution: 4 μg/ml.
Western blotting: Non-reducing conditions.

Reactivity

Human, Non-human primates

Immunogen

A crude mixture of human urinary proteins precipitated by ammonium sulphate from the urine of a patient suffering from proteinuria.

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

LPS-receptor, LPSR, MCLR

Antigen description

CD14 is a 55 kDa GPI-anchored glycoprotein, constitutively expressed on the surface of mature monocytes, macrophages, and neutrophils, where it serves as a multifunctional lipopolysaccharide receptor. It is also released to the serum both as a secreted and enzymatically cleaved GPI-anchored form. CD14 binds lipopolysaccharide molecule in a reaction catalyzed by lipopolysaccharide-binding protein (LBP), an acute phase serum protein. The soluble sCD14 is able to discriminate slight structural differences between lipopolysaccharides and is important for neutralization of serum allochthonous lipopolysaccharides by reconstituted lipoprotein particles. CD14 affects allergic, inflammatory and infectious processes.

Entrez Gene ID 929

UniProt ID P08571

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD14 (MEM-18) purified antibody (concentration in sample 0,6 μg/ml, GAM APC).

Separation of human monocytes (red-filled) from CD14 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of peripheral whole blood stained using anti-human CD14 (MEM-18) purified antibody (concentration in sample 0,6 μg/ml, GAM APC).

General references:

Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J Biol Chem. 1995 Jul 21;270(29):17237-42.
PubMed

Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr Allergy Asthma Rep. 2007 Nov;7(6):436-43.
PubMed

Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J Immunol. 2007 Dec 1;179(11):7674-83.
PubMed

Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab. 2003 Apr;88(4):1780-4.
PubMed

Product specific references:

Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I: Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol. 1986 Dec;16(12):1583-9.
PubMed

Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med. 2002 Oct 21;196(8):1017-24.
PubMed

Ohradanova-Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco-Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. Front Immunol. 2018 Apr 27;9:852.
PubMed

Bazil V, Baudys M, Hilgert I, Stefanova I, Low MG, Zbrozek J, Horejsi V: Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol. 1989 Jul;26(7):657-62.
PubMed

Leukocyte Typing III., McMichael A.J. et al. (Eds.), Oxford University Press (1987).

Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).

Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).

Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).

Iwaki D, Nishitani C, Mitsuzawa H, Hyakushima N, Sano H, Kuroki Y: The CD14 region spanning amino acids 57-64 is critical for interaction with the extracellular Toll-like receptor 2 domain. Biochem Biophys Res Commun. 2005 Mar 4;328(1):173-6.
PubMed

Angel CE, Lala A, Chen CJ, Edgar SG, Ostrovsky LL, Dunbar PR: CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. Int Immunol. 2007 Nov;19(11):1271-9.
PubMed

Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19(5):675-84.
PubMed

Weiss TS, Lichtenauer M, Kirchner S, Stock P, Aurich H, Christ B, Brockhoff G, Kunz-Schughart LA, Jauch KW, Schlitt HJ, Thasler WE. Hepatic progenitor cells from adult human livers for cell transplantation. Gut. 2008 Aug;57(8):1129-38.
PubMed

Stöckl J, Majdic O, Fischer G, Maurer D, Knapp W: Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-A1-restricted, hapten-specific CTL. J Immunol. 2001 Sep 1;167(5):2724-33.
PubMed

Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun. 2001 Jun;69(6):3772-81.
PubMed